Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

May 19, 2005

By Jennifer Boggs

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Zelos' Series B Round Nets $42M For PTH Drug Pipeline

May 19, 2005

By Jennifer Boggs

Zelos Therapeutics Inc. raised $42.5 million in a Series B round to fund clinical trials of its next-generation parathyroid hormone (PTH) analogue in four indications. (BioWorld Today)

Licensing Deal Gives Spectrum Radiation Adjunct For Cancer

May 18, 2005

By Jennifer Boggs

Licensing Deal Gives Spectrum Radiation Adjunct For Cancer

May 18, 2005

By Jennifer Boggs

Reverse Merger Gives Rexahn Listing On OTC Bulletin Board

May 17, 2005

By Jennifer Boggs

Xcyte Calls Off Cancer Trial, Shifts Focus To HIV Program

May 17, 2005

By Jennifer Boggs

Xcyte Calls Off Cancer Trial, Shifts Focus To HIV Program

May 17, 2005

By Jennifer Boggs

Reverse Merger Gives Rexahn Listing On OTC Bulletin Board

May 17, 2005

By Jennifer Boggs

Onyx, Bayer Begin Phase III Sorafenib Trial In Melanoma

May 16, 2005

By Jennifer Boggs

Spherics Gets $26M To Push Bioadhesive Drug Delivery

May 13, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...